Insulin, Neurogenetics and Memory in Alzheimer's Disease

This study has been completed.
Sponsor:
Information provided by:
Department of Veterans Affairs
ClinicalTrials.gov Identifier:
NCT00018382
First received: July 3, 2001
Last updated: January 20, 2009
Last verified: December 2004
  Purpose

This study examines the use of insulin-sensitizing compounds, as therapeutic agents for cognitive impairment in Alzheimer's disease.


Condition Intervention Phase
Alzheimer Disease
Drug: rosiglitazone
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Insulin, Neurogenetics and Memory in Alzheimer's Disease: A Novel Therapeutic Approach

Resource links provided by NLM:


Further study details as provided by Department of Veterans Affairs:

Study Start Date: October 1999
Estimated Study Completion Date: March 2003
  Eligibility

Ages Eligible for Study:   55 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Men and women with mild Alzheimer's Disease without serious medical or psychiatric comorbid conditions.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00018382

Locations
United States, Washington
VA Puget Sound Health Care System
Seattle, Washington, United States, 98108
Sponsors and Collaborators
Investigators
Investigator: Steven Kahn, M.D.
Investigator: Sanjay Asthana, M.D.
Investigator: Alfred Fujimoto, M.D.
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00018382     History of Changes
Other Study ID Numbers: AGCG-012-98S
Study First Received: July 3, 2001
Last Updated: January 20, 2009
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders
Rosiglitazone
Hypoglycemic Agents
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on August 21, 2014